News

The Foundation for Sarcoidosis Research (FSR) is launching a series of mindfulness and meditation workshops — all as free, live webinars — to support people with sarcoidosis and those caring for them. The workshop series will focus on discussing the physical and mental benefits of meditation and…

Corticosteroids, a type of anti-inflammatory medication, is the most-prescribed treatment for people with sarcoidosis, a study in a U.S. population shows. Also, the study found, a small percentage of these patients are receiving biological therapies (those using compounds derived from living organisms), despite not being approved in…

The World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) and the Foundation for Sarcoidosis Research (FSR) have recognized the University of Miami Sarcoidosis Program as a Sarcoidosis Center of Excellence. This recognition is granted to multidisciplinary teams of medical professionals, who share a specialized facility that…

Relative to the general population, people with sarcoidosis are at higher long-term risk of heart failure and other heart problems, a large Danish data study suggests. Its researchers recommend regular monitoring of cardiac issues across this patient group. The study, “Long-Term Adverse Cardiac Outcomes in Patients With…

A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like the option of continuing its use in future appointments, a series of surveys found. The surveys were conducted by the National Organization for Rare Disorders (NORD) and involved more than 800…

Kidney involvement, heart wall abnormalities, and left heart failure were identified as risk factors for a relapse of cardiac sarcoidosis, a long-term study involving more than 150 patients suggests. Immunosuppressant treatment with cyclophosphamide was also linked to a significantly lower risk of cardiac relapse in this patient population.